Physician profile
Amanda Russo
NPI 1952881229
$3,499.42
in general payments reported to CMS, 2019-2025
22 companies · $648 in 2025
The $648 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $836 · 2024: $2,016 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294 · Travel and Lodging: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.50 |
| Travel and Lodging | $1,205.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,559.03 | 2024 | Cardiomems, Esprit |
| Merck Sharp & Dohme LLC | $441.63 | 2023-2025 | Verquvo, Capvaxive, Januvia |
| Cvrx, INC. | $184.13 | 2024-2025 | Barostim Neo System |
| Bridgebio Pharma, INC. | $178.76 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $144.52 | 2023 | Inspire |
| Amgen INC. | $130.87 | 2023-2024 | Repatha |
| Lexicon Pharmaceuticals, INC. | $114.34 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $113.16 | 2023-2024 | Xarelto |
| Esperion Therapeutics, INC. | $111.79 | 2023-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.70 | 2023-2025 | Lifevest |
| Novo Nordisk INC | $76.85 | 2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $67.41 | 2023-2025 | Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $38.55 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $37.64 | 2023-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $35.79 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $32.23 | 2024 | Arcalyst |
| Regeneron Pharmaceuticals, INC. | $27.06 | 2025 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $22.67 | 2024 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $19.43 | 2025 | |
| Lilly USA, LLC | $18.21 | 2023 | Trulicity, Mounjaro |
| Scpharmaceuticals INC. | $17.86 | 2023 | |
| Pfizer INC. | $17.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.